Core Area
Education
Strategic Area
Graduate and post-graduate program development and refinement aligned with areas of learner and industry and sector demand
Goal Status
In Progress
Achieved Goals
- Ministry approved Graduate Diploma in Pharmacy Leadership (July 2023); admissions accepted spring 2024; students entered the program (Sep 2024).
- Graduate portfolio held curriculum review meetings with research groups to refine and renew the curriculum for each specialty area (including Nanomedicine, Chemical Biology, Pharmacometrics, Pharmacy Education Research Leadership, Health Outcomes, and Molecular and Systems Pharmacology); groups reviewed the overall graduate program requirements and identified gaps in current course offerings (summer 2023); the group worked to implement the action items (2024).
- Senate approved new course, PHAR 520 (3) Applied Omics Science for Drug Discovery and Development, to the grad curriculum; this course aimed to fill a curricular gap, and expose students to key genomic technologies and computational approaches driving advances in prognostics, diagnostics, and treatment (spring 2024).
- Senate approved proposal to create two versions of the PHAR 549 Master’s Thesis course to better suit the varied academic backgrounds of our incoming MSc students and the diverse types of the research our MSc students do: the existing 12-credit version and a new 18-credit version (spring 2024).
- Approved new part-time study options for our MSc and PhD programs, designed to provide greater flexibility for working professionals who wish to pursue advanced studies while balancing their professional and personal commitments (fall 2025).
- Updated handbooks for graduate students, postdoctoral fellows and supervisors to include visual timelines for degree milestones and separate MSc and PhD program details, making it more user-friendly for students to navigate (fall 2025).